

16. (New) A method of treating abnormal lipid metabolism comprising the coordinated administration of a statin selected from the group consisting of lovastatin, simvastatin, provastatin and fluvastatin and an alkanoyl L-carnitine selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, valeryl L-carnitine and isovaleryl L-carnitine or one of their pharmacologically acceptable salts, provided the combination of simvastatin with propionyl L-carnitine is excluded.

21 17. (New) A method of lowering cholesterolaemia and triglyceridaemia associated with abnormal lipid metabolism comprising the coordinated administration of a statin selected from the group consisting of lovastatin, simvastatin, provastatin and fluvastatin and an alkanoyl L-carnitine selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, valeryl L-carnitine and isovaleryl L-carnitine or one of their pharmacologically acceptable salts, provided the combination of simvastatin with propionyl L-carnitine is excluded.

18. (New) An orally or parentally administerable pharmaceutical composition which consists essentially of a statin selected from the group consisting of lovastatin, simvastatin, provastatin and fluvastatin and an alkanoyl L-carnitine selected from the group consisting of acetyl L-carnitine, propionyl L-carnitine, butyryl L-carnitine, valeryl L-carnitine and isovaleryl L-carnitine or one of their pharmacologically acceptable salts, provided the combination of simvastatin with propionyl L-carnitine is excluded, in a pharmaceutically acceptable carrier or diluent.